Next Article in Journal
Depression Symptom Patterns and Social Correlates among Chinese Americans
Previous Article in Journal
Blood Flow and Continuous EEG Changes during Symptomatic Plateau Waves
Previous Article in Special Issue
Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Brain Sci. 2018, 8(1), 15; https://doi.org/10.3390/brainsci8010015

Glioblastoma under Siege: An Overview of Current Therapeutic Strategies

Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
*
Author to whom correspondence should be addressed.
Received: 22 November 2017 / Revised: 8 January 2018 / Accepted: 12 January 2018 / Published: 16 January 2018
(This article belongs to the Special Issue Advances in Adult and Pediatric Brain Tumor Management)
View Full-Text   |   Download PDF [245 KB, uploaded 16 January 2018]

Abstract

Glioblastoma is known to be one of the most lethal and untreatable human tumors. Surgery and radiotherapy in combination with classical alkylating agents such as temozolomide offer little hope to escape a poor prognosis. For these reasons, enormous efforts are currently devoted to refine in vivo and in vitro models with the specific goal of finding new molecular aberrant pathways, suitable to be targeted by a variety of therapeutic approaches, including novel pharmaceutical formulations and immunotherapy strategies. In this review, we will first discuss current molecular classification based on genomic and transcriptomic criteria. Also, the state of the art in current clinical practice for glioblastoma therapy in the light of the recent molecular classification, together with ongoing phases II and III clinical trials, will be described. Finally, new pharmaceutical formulations such as nanoparticles and viral vectors, together with new strategies entailing the use of monoclonal antibodies, vaccines and immunotherapy agents, such as checkpoint inhibitors, will also be discussed. View Full-Text
Keywords: monoclonal antibodies; alkylating agents; nanoparticles; immunotherapy monoclonal antibodies; alkylating agents; nanoparticles; immunotherapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Paolillo, M.; Boselli, C.; Schinelli, S. Glioblastoma under Siege: An Overview of Current Therapeutic Strategies. Brain Sci. 2018, 8, 15.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Brain Sci. EISSN 2076-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top